Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas
Both temozolomide and the regimen of procarbazine, lomustine, and vincristine (PCV) prolong survival in patients with malignant gliomas when used as an adjuvant to radiotherapy (temozolomide in patients with newly diagnosed glioblastoma and 1p/19q non-codeleted anaplastic gliomas and PCV in both tho...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 April 2018
|
| In: |
Cancer
Year: 2018, Volume: 124, Issue: 13, Pages: 2674-2676 |
| ISSN: | 1097-0142 |
| DOI: | 10.1002/cncr.31371 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.31371 Verlag, lizenzpflichtig, Volltext: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31371 
|
| Author Notes: | Wolfgang Wick, Frank Winkler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1692607650 | ||
| 003 | DE-627 | ||
| 005 | 20220818013413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200316s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.31371 |2 doi | |
| 035 | |a (DE-627)1692607650 | ||
| 035 | |a (DE-599)KXP1692607650 | ||
| 035 | |a (OCoLC)1341310418 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 245 | 1 | 0 | |a Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas |c Wolfgang Wick, Frank Winkler |
| 264 | 1 | |c 26 April 2018 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.03.2020 | ||
| 520 | |a Both temozolomide and the regimen of procarbazine, lomustine, and vincristine (PCV) prolong survival in patients with malignant gliomas when used as an adjuvant to radiotherapy (temozolomide in patients with newly diagnosed glioblastoma and 1p/19q non-codeleted anaplastic gliomas and PCV in both those patients with newly diagnosed high-risk low-grade gliomas and those with 1p/19q codeleted anaplastic oligodendrogliomas). However, there is debate regarding the appropriate alkylating regimen to use for individuals with glial neoplasms. Balancing survival advantages versus risks of toxicity and impact on quality of life are important elements of this debate. | ||
| 700 | 1 | |a Winkler, Frank |d 1971- |e VerfasserIn |0 (DE-588)120794586 |0 (DE-627)704993104 |0 (DE-576)292388586 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d New York, NY : Wiley-Liss, 1948 |g 124(2018), 13, Seite 2674-2676 |h Online-Ressource |w (DE-627)271350334 |w (DE-600)1479932-7 |w (DE-576)078590884 |x 1097-0142 |7 nnas |a Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas |
| 773 | 1 | 8 | |g volume:124 |g year:2018 |g number:13 |g pages:2674-2676 |g extent:3 |a Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas |
| 856 | 4 | 0 | |u https://doi.org/10.1002/cncr.31371 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31371 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200316 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 120794586 |a Winkler, Frank |m 120794586:Winkler, Frank |d 910000 |d 911100 |e 910000PW120794586 |e 911100PW120794586 |k 0/910000/ |k 1/910000/911100/ |p 2 |y j | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1692607650 |e 3608929991 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1692607650","physDesc":[{"extent":"3 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"271350334","disp":"Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomasCancer","origin":[{"dateIssuedKey":"1948","dateIssuedDisp":"1948-","publisherPlace":"New York, NY","publisher":"Wiley-Liss"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 06.12.2011"],"title":[{"title_sort":"Cancer","title":"Cancer","subtitle":"interdisciplinary international journal of the American Cancer Society"}],"titleAlt":[{"title":"Cancer cytopathology"}],"pubHistory":["1.1948 -"],"id":{"issn":["1097-0142"],"eki":["271350334"],"doi":["10.1002/(ISSN)1097-0142"],"zdb":["1479932-7"]},"part":{"volume":"124","year":"2018","text":"124(2018), 13, Seite 2674-2676","extent":"3","issue":"13","pages":"2674-2676"}}],"person":[{"family":"Wick","role":"aut","given":"Wolfgang","display":"Wick, Wolfgang"},{"display":"Winkler, Frank","given":"Frank","role":"aut","family":"Winkler"}],"origin":[{"dateIssuedDisp":"26 April 2018","dateIssuedKey":"2018"}],"title":[{"title":"Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas","title_sort":"Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas"}],"note":["Gesehen am 16.03.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["Wolfgang Wick, Frank Winkler"]},"id":{"eki":["1692607650"],"doi":["10.1002/cncr.31371"]}} | ||
| SRT | |a WICKWOLFGAREGIMENOFP2620 | ||